Adenoviruses: Basic Biology to Gene Therapy

Автор(ы):Seth Perm
Год изд.:1999
Описание: From the publisher: «Landes Bioscience produces books in six Intelligence Unit series: Medical, Molecular Biology, Neuroscience, Tissue Engineering, Biotechnology and Environmental. The authors of our books are acknowledged leaders in their fields. Topics are unique; almost without exception, no similar books exist on these topics. Our goal is to publish books in important and rapidly changing areas of bioscience for sophisticated researchers and clinicians. To achieve this goal, we have accelerated our publishing program to conform to the fast pace at which information grows in bioscience. Most of our books are published within 90 to 120 days of receipt of the manuscript. We would like to thank our readers for their continuing interest and welcome any comments or suggestions they may have for future books.»
Adenoviruses: Basic Biology to Gene Therapy — обложка книги. Обложка книги.
Section I: Discovery and Structure of Adenoviruses
  1. Discovery and Classification of Adeno viruses [1]
   Harold S. Ginsberg
      Discovery of Adenoviruses [1]
      Classification [2]
  2. Adenovirus Capsid Proteins [5]
    John J. Rux and Roger M. Burnett
      Virion Architecture [5]
      Major Coat Proteins [7]
      Minor Coat Proteins [14]
      Future Directions [15]
  3. Organization of the Adeno viral Genome [17]
    Jane Flint
      Organization of Coding Sequences [18]
      Other Important Features [26]
      Sequences That Fulfill Multiple Functions [27]
      Conclusion [27]
Section II: Adenovirus Life Cycle
  4. Entry of Adenovirus into Cells [31]
    Prem Seth
      Binding of Adenovirus to the CeU Receptor, and its Entry into the Endosomes [31]
      Adenovirus-Mediated Lysis of Endosome Membrane: Role of Low pH and Penton Base [33]
      Vectorial Movement of the Adenovirus into the Nucleus [33
      Conclusion [35]
  5. Early Gene Expression [39]
    Philip E. Branton
      Adenovirus Genes and Products [39]
      Early Region 1A (E1A) [40]
      Regulation of Gene Expression by El A Products [42]
      Early Region IB (E1B) [46]
      Early Region 2 (E2) [50]
      VA RNA and Regulation of Protein Synthesis [50]
      Early Region 3 (E3) [50]
      gp19K [50]
      Early Region 4 (E4) [51]
      Adenoviruses and Adenoviral Products as Therapeutic Agents [54]
      Conclusion [55]
  6. Adenovirus DNA Replication [59]
    Muralidhara Ramachandra and R. Padmanabhan
      Viral Genome and the Origin of DNA Replication [59]
      E2 Region and Its Regulation [59]
      Viral Replication Proteins [60]
      Cellular Factors Required for Replication [62]
      Initiation and Elongation of DNA Replication [63]
      Conclusion [65]
  7. Adenovirus Late Gene Expression [69]
    Julie Boyer and Gary Ketner
      Structure of the Late RNAs [69]
      Transcriptional Activation [72]
      Non-MLTU Late Proteins [73]
      Regulation of Polyadenylation [73]
      Regulation of Splicing [74]
      Nuclear Organization [74]
      mRNA Export [75]
      Inhibition of Translation of Host mRNA [76]
      Conclusion [76]
  8. Role of Endoprotease in Adenovirus Infection [79]
    Joseph Weber
  9. Adenovirus Assembly [85]
    Susanne I. Schmid and Patrick Hearing
      Assembly Intermediates [85]
      Incomplete Particles of Adenovirus [85]
      Polar Encapsidation of Adenovirus DNA [86]
      Cis-acting Sequences Involved in Packaging Specificity [86]
      Trans-acting Components May Be Involved in Packaging [88]
      Virus Release from Infected CeUs [88]
Section III: Adenoviral Vectors for Gene Therapy: Preclinical Research
  10. Development of Adenoviral Vectors for Gene Therapy [91]
    Dai Katayose and Prem Seth
      Recombinant Adenoviral Vectors [91]
      Adenovirally-Mediated Enhancement of DNA Delivery and the Concepts of Molecular Conjugates [96]
      Conclusion [99]
  11. Adenoviral Vectors for Cancer Gene Therapy [103]
    Pretn Seih, YuKatayose, andAmolN.S. Rakkar
      Direct: Toxic Transgene Products [104]
      Indirect: Immunomodulation Through Recombinant Adenoviral Vectors [111]
      Other Novel Strategies [113]
      Conclusion [115]
  12. Adenoviral Vectors for Cardiovascular Diseases [121]
    Noel M. Caplice, Timothy O'Brien, and Robert D. Simari
      Vector Requirements for Cardiovascular Disease [121]
      Comparisons with Other Vectors [122]
      Potential for Toxicity [122]
      Specific Enhancements of Adenoviral Vectors for Cardiovascular Targets [124]
      Preclinical and Clinical Studies of Cardiac Gene Transfer Using Adenoviral Vectors [124]
      Preclinical Studies of Vascular Gene Transfer Using Adenoviral Vectors [125]
      Conclusion [126]
  13. lAP-Based Gene Therapy for Neurodegenerative Disorders [129]
    Stephen J. Crocker, DaigenXu, Charlie S.Thompson, Peter Liston, and George S. Robertson
      The IAP Gene Family [130]
      Function of IAP Proteins [130]
      IAP Gene Therapy for Stroke [131]
      IAP Gene Therapy for Optic Neurodegeneration [132]
      IAP Gene Therapy for Parkinson's Disease [133]
      Prospects for lAP-based Gene Therapy [135]
  14. Adenovirus Vectors for Therapeutic Gene Transfer to Skeletal Muscles [139]
    Josephine Nalbantoglu, Basil J. Petrof, Renald Gilbert, and George Karpati
  15. Adenovirus-Mediated Gene Transfer: Applications in Lipoprotein Research [147]
    Silvia Santamarina-Fojo and Marcelo J.A. Amar
      Analysis of Gene Function in Lipoprotein Metabolism [147]
      Gene Replacement Therapy in Animal Models of Hyperlipidemia and Atherosclerosis [148]
      Expression of Genes that Modulate Lipid Metabolism by Enhancing Alternative Lipoprotein Pathways [149]
      Structure-Function Analysis of Proteins Modulating
      Lipoprotein Metabolism [150]
  16. Correction of Serum Protein Deficiencies with Recombinant Adenoviral Vectors [157]
    James N. Higginbotham and Prem Seih
      al-antitrypsin Deficiency [157]
      Factor VIII and Factor IX Deficiency [158]
      Erythropoietin Deficiency [160]
      Other Potential Uses of AdenoviraUy-Delivered Serum
      Protein [160]
      Conclusion [161]
  17. Adenoviral Vectors for Vaccines [163]
    Bernard Klonjkowski, Caroline Denesvre, and Marc Eloit
      Several Deletion Mutants with Different Properties
      Can be Used [163]
      Efficacy and Safety of Adenovirus-Vectored Vaccines [165]
      Comparison of Replicative and Nonreplicative Viruses [167]
      Mechanisms of Immune Response Induction by Recombinant Adenoviruses [167]
      Prospects for Use [169]
      Conclusion [171]
Section IV: Targetable Adenoviral Vectors
  18. Strategies to Adapt Adenoviral Vectors for Gene Therapy Applications [175]
    Joanne T. Douglas, Meizhen Feng, and David T. Curiel
      The Generation of Targeted Adenoviral Vectors by Immunological Modifications of the Fiber Protein [175]
      Achievement of Long-Term Heterologous Gene Expression via Adenoviral Vectors [177]
  19. Adenovirus-AAV Combination Strategies for Gene Therapy [183]
    Krishna J. Fisher
      Adenovirus Vector Development [183]
      Adenovirus-AAV Blueprint [184]
      Conclusion [189]
  20. Transcriptional and Promoter-Driven Control of Adenovirus-Mediated Gene Expression [191]
    Yoko Yoshida and Hirofumi Hamada
      Transcriptional and Promoter-Driven Targeting of Adenoviral Vectors [191]
      Tetracycline -Inducible System for Adenoviral Vectors [192]
      VSVG-Pseudotyped Retroviral Packaging System Through Adenovirus-Mediated Inducible Gene Transduction [198]
      Future Applications [198]
  21. Development of an E1B, 55 kDa Gene-Deleted, Selectively Replicating Adenoviras for the Treatment of Cancer: ONYX-015 [201]
    David H. Kirn
      Development of ONYX-015 (dl1520) [201]
      Combination Therapy with a Replicating Adenovirus and Chemotherapeutics [202]
      Clinical Development of ONYX-015 [203]
      Conclusion [205]
  22. Adenoviral Vectors for the Manipulation of Human Hematolymphoid Cells: Purging and Other Applications [207]
    Timothy C. Meeker, Joanne M. Wroblewski, and Prem Seth
      Gene Transfer to Bone Marrow-Derived Cells: Lymphocytes [208]
      Gene Transfer to Bone Marrow-Derived Cells: Myeloid Cells [208]
      HSC are Relatively Resistant to Transduction Using Adenoviral Vectors [209]
      Purging: Exploiting The Resistance of HSC to Transduction [211]
      Purging: Future Directions [213]
      Conclusion [214]
      Section V: Adenoviral Vectors: Safety Issues
  23. Adenovirus Transformation and Tumorigenicity [217]
    Robert P. Ricciardi
      E1A Activates the Cell Cycle and Induces Proliferation in Transformed Cells [217]
      E1B Blocks Growth Arrest and Apoptosis Induced by E1A in Transformed Cells [218]
      Adenovirus Tumorigenesis—MHC Class I Downregulation as a Means of Immunoescape [220]
      A Connection Between Tumorigenesis and Viral Persistence [224]
      ElA-Mediated Tumorigenesis Involves More than MHC Class I Downregulation [224]
      Conclusion [225]
  24. Homologous Recombination Between Exogenous and Integrated Adenovirus DNA Sequences [229]
    C. S. H. Young and Gregory J. Duigou
      A Comparison of Extrachromosomal Homologous
      Recombination with that Occurring Between
      Extrachromosomal and Integrated Sequences [229]
      Recombination Between Exogenous Viral DNA and Sequences Integrated Into the CeUular Genome [230]
      Can Adenovirus be Used to Target Homologous Sequences for Purposes of Gene Modification? [232]
      Potential Investigation of RCA Formation [233]
  25. Adenovirus-Induced Pathogenesis [237]
    Harold S. Ginsberg
      Molecular Pathogenesis of Adenovirus Pneumonia [237]
      Discussion [241]
  26. Adenoviras-Host Interactions to Subvert the Host Immune System [243]
    William S. M. Wold and Ann E. Tollefson
  27. Implications of the Innate Immune System for Adenovirus-Mediated Gene Transfer [251]
    Kazuhisa Otake and Bruce C. Trapnell
      Definition of Innate Immunity [252]
      Innate Immunity to Infection in the Lung [252]
      Innate Immunity to Adenovirus-Mediated In Vivo Gene Transfer [255]
      Conclusion [259]
  28. Host Immune Responses to Recombinant Adenoviral Vectors [261]
    Johanne M. Kaplan
      Humoral Immunity [261]
      Cellular Immunity [264]
      Conclusion [268]
      Section VI: Clinical Trials with Adenoviral Vectors
  29. AdCFTR for Cystic Fibrosis [273]
    Samuel C. Wadsworth
      Advantages of Ad Vectors for Cystic Fibrosis (CF) Gene Therapy [273]
      CF Gene Transfer Clinical Studies with Ad Vectors [273]
      Properties of AdCFTR Vectors [273]
      Clinical Strategies [274]
      Results From Clinical Studies [274]
      Conclusion [276]
  30. Ad-p53 Clinical Trial in Patients with Squamous Cell Carcinoma of the Head and Neck [279]
    Gary L. dayman, Douglas K. Frank, and Patricia A. Bruso
      Review of Current Research [280]
      Conclusion [281]
  31. Adenoviral Vectors for Liver Cancer—Clinical Trials [285]
      RagaiR. Mitry, Catherine E. Sarraf, andNagyA. Habib
      Gene Therapy for Liver Cancers [285]
      Conclusion [288]
  32. Opportunities for p53 Tumor Suppressor Gene Therapy in Ovarian and Other Peritoneal Cancers [293]
      Loretta L. Nielsen, Mark Pegram, Beth Karlan, John Elkas, and Jo Ann Horowitz
      Preclinical Pharmacology: Intraperitoneal Administration of p53 Adenovirus [293]
      Ad-p53 Gene Therapy Combined with Chemotherapy [294]
      Tumor/Host Factors Predictive of Response to p53 Adenovirus [296]
      Clinical Results: Intraperitoneal Administration of p53 Adenovirus [296]
      Conclusion [300]
  33. Adenoviral Gene Therapy for Malignant Pleural Mesothelioma [303]
      Daniel H. Sterman, Larry R. Kaiser, and Steven M. Albelda
      Gene Therapy Using the Herpes Simplex Thymidine Kinase Gene [303]
      Preclinical Data: Animal and Toxicity Studies [304]
      Clinical Data: Results from Phase I Clinical Trial [304]
      Problems and Future Approaches [308]
      Conclusion [308]
Формат: djvu
Размер:3952914 байт
Рейтинг: 59 Рейтинг
Открыть: Ссылка (RU)